Cardiovascular disturbances in COVID-19 : an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2

dc.contributor.authorLawal, Ismaheel Opeyemi
dc.contributor.authorKgatle, Mankgopo
dc.contributor.authorMokoala, Kgomotso M.G.
dc.contributor.authorFarate, Abubakar
dc.contributor.authorSathekge, Mike Machaba
dc.date.accessioned2022-07-19T12:23:44Z
dc.date.available2022-07-19T12:23:44Z
dc.date.issued2022-03
dc.description.abstractSevere acute respiratory coronavirus-2 (SARS-Co-2) is the causative agent of coronavirus disease-2019 (COVID-19). COVID-19 is a disease with highly variable phenotypes, being asymptomatic in most patients. In symptomatic patients, disease manifestation is variable, ranging from mild disease to severe and critical illness requiring treatment in the intensive care unit. The presence of underlying cardiovascular morbidities was identified early in the evolution of the disease to be a critical determinant of the severe disease phenotype. SARS-CoV-2, though a primarily respiratory virus, also causes severe damage to the cardiovascular system, contributing significantly to morbidity and mortality seen in COVID-19. Evidence on the impact of cardiovascular disorders in disease manifestation and outcome of treatment is rapidly emerging. The cardiovascular system expresses the angiotensin-converting enzyme-2, the receptor used by SARS-CoV-2 for binding, making it vulnerable to infection by the virus. Systemic perturbations including the so-called cytokine storm also impact on the normal functioning of the cardiovascular system. Imaging plays a prominent role not only in the detection of cardiovascular damage induced by SARS-CoV-2 infection but in the follow-up of patients' clinical progress while on treatment and in identifying long-term sequelae of the disease.en_US
dc.description.departmentNuclear Medicineen_US
dc.description.urihttp://www.biomedcentral.com/bmccardiovascdisorden_US
dc.identifier.citationLawal, I.O., Kgatle, M.M., Mokoala, K., Farate, A. & Sathekge, M.M. Cardiovascular disturbances in COVID-19: an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2. BMC Cardiovascular Disorders 2022 Mar 9;22(1):93. doi: 10.1186/s12872-022-02534-8.en_US
dc.identifier.issn1471-2261 (online)
dc.identifier.otherhttps://doi.org/10.1186/s12872-022-02534-8
dc.identifier.urihttps://repository.up.ac.za/handle/2263/86296
dc.language.isoenen_US
dc.publisherBMCen_US
dc.rights© The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.subjectCardiovascular disordersen_US
dc.subjectMyocarditisen_US
dc.subjectTakotsubo cardiomyopathyen_US
dc.subjectThromboembolismen_US
dc.subjectCOVID-19 pandemicen_US
dc.subjectCoronavirus disease 2019 (COVID-19)en_US
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_US
dc.subjectPositron emission tomography (PET)en_US
dc.titleCardiovascular disturbances in COVID-19 : an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lawal_Cardiovascular_2022.pdf
Size:
1.41 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: